Amicus Therapeutics to Participate in September Conferences
Amicus Therapeutics (Nasdaq: FOLD) has announced its involvement in several important investor conferences this September. This participation underscores the company's dedication to engaging with investors and sharing insights into their innovative therapies aimed at addressing rare diseases.
Details of Upcoming Presentations
One of the key events this month is the Morgan Stanley 22nd Annual Global Healthcare Conference, which will be held in New York. Amicus management is scheduled to present on Thursday, offering valuable insights into their ongoing projects and future objectives. Furthermore, they will also be featured at the Cantor Global Healthcare Conference 2024 on September 17, where in-depth discussions about their developmental pipeline are anticipated.
Wells Fargo Healthcare Conference
Alongside these events, Amicus will participate in the 2024 Wells Fargo Healthcare Conference on September 6. This conference provides another platform for the company to showcase its advancements and connect with healthcare investors.
Commitment to Rare Diseases
Amicus Therapeutics is committed to discovering, developing, and delivering innovative medicines for individuals affected by rare diseases. Their patient-centered approach ensures that treatments are tailored to meet the unique needs and experiences of patients, thereby enhancing their effectiveness within the healthcare system.
Innovative Pipeline
The company has made significant progress in establishing a strong pipeline filled with first- or best-in-class medications aimed at various rare conditions. Their commitment extends beyond advancing science; they strive to provide hope and solutions to patients who have limited treatment options.
Company Overview
As a global biotechnology company, Amicus Therapeutics is making noteworthy contributions to the field of rare diseases. With a focus on improving the quality of life for patients, Amicus is continually working to expand its therapeutic offerings. The company maintains transparency with investors, regularly sharing updates on progress and challenges through various communication channels, especially during investor conferences.
Contact Information
For investors seeking more information, Amicus Therapeutics has made contact details available within their investor relations team. Andrew Faughnan, Vice President of Investor Relations, can be reached at (609) 662-3809 or via email. Media inquiries can be directed to Diana Moore, Head of Global Corporate Affairs.
Frequently Asked Questions
What is the significance of Amicus Therapeutics attending these conferences?
By attending investor conferences, Amicus Therapeutics can showcase their developments, engage with investors, and emphasize their commitment to treating rare diseases.
What therapies does Amicus Therapeutics focus on?
Amicus Therapeutics specializes in developing high-quality medicines specifically tailored for patients with rare diseases.
How can investors find more information on Amicus Therapeutics?
Investors can learn more about Amicus Therapeutics by visiting their official website and checking the investor section for the latest updates and resources.
Who can be contacted for investor relations inquiries?
Investors can contact Andrew Faughnan, Vice President of Investor Relations at Amicus Therapeutics, for any inquiries.
What are the themes of the presentations Amicus will deliver at the events?
The presentations will focus on the advancements in the company’s pipeline, their approach to treating rare diseases, and their future goals within the biotechnology sector.